a) prostate specific antigen (PSA) is specific to the prostate but not to prostate cancer b) PSA cannot discriminate different cancer stages c) The introduction of PSA as a screening test has led to substantial 'overdiagnosis' d) PSA screening does not affect prostate cancer mortality
Changes in absorption over time, high intrapatient variability and lack of dose proportionality constitute further limitations of the C(2) monitoring concept in the early post- transplant phase
Nephrology Dialysis Transplantation Vol. 20
